

## Imcivree® (setmelanotide) - Expanded indication

- On December 20, 2024, Rhythm Pharmaceuticals announced the FDA approval of Imcivree (setmelanotide), to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to:

   (1) Bardet-Biedl syndrome (BBS) and (2) pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance.
  - Imcivree was previously approved for this indication in patients aged 6 years and older.
- BBS and POMC, PCSK1 and LEPR deficiencies are rare melanocortin-4 receptor pathway diseases characterized by impaired satiety, abnormal food-seeking behaviors, and early-onset obesity.
- The approval of Imcivree for the expanded indication was based on a study in 12 pediatric patients aged 2 to less than 6 years with obesity due to POMC, PCSK1, or LEPR deficiency or BBS. Imcivree dose titration occurred over an 8-week period, followed by a 44-week open-label treatment period with Imcivree.
  - The mean percent change in body mass index (BMI) after 52 weeks of Imcivree treatment was -33.8%, -13.1%, and -9.7% in patients with POMC deficiency, LEPR deficiency, and BBS, respectively.
- The recommended starting dosage of Imcivree is 0.5 mg (0.05 mL) injected subcutaneously once daily for 2 weeks in pediatric patients aged 2 to less than 6 years.
- Refer to the Imcivree drug label for titration instructions and dosing in patients 6 years and older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.